uniQure NV (NASDAQ:QURE) was up 8.4% during trading on Tuesday . The company traded as high as $8.06 and last traded at $7.99, with a volume of 406,515 shares trading hands. The stock had previously closed at $7.37.

A number of equities research analysts recently commented on QURE shares. Piper Jaffray Cos. reissued a “buy” rating on shares of uniQure NV in a research note on Thursday, June 30th. Chardan Capital reissued a “buy” rating on shares of uniQure NV in a research note on Monday, July 18th. Leerink Swann reaffirmed a “positive” rating and set a $27.00 price target on shares of uniQure NV in a research note on Tuesday. Jefferies Group set a $28.00 price target on shares of uniQure NV and gave the stock a “buy” rating in a research note on Thursday, July 28th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of uniQure NV in a research note on Thursday, July 28th. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $29.10.

The company’s market cap is $197.56 million. The stock has a 50 day moving average of $7.63 and a 200-day moving average of $12.15.

uniQure NV (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 31st. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. Equities analysts anticipate that uniQure NV will post ($3.51) EPS for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.